Global Blood Therapeutics Zacks

February 11, 2021 Post a Comment

This biopharmaceutical company is expected to post quarterly loss. View Global Blood Therapeutics Inc.

Bn7a 9ogw7u0fm

Some better-ranked stocks in the healthcare sector include Acorda Therapeutics Inc.

Global blood therapeutics zacks. External links are being provided as a convenience and for informational purposes only. Nov 6 2020 1054AM EST Global Blood Therapeutics Inc. GBT investment stock information.

NASDAQGBT will post sales of 4324 million for the current quarter according to Zacks. GBT Quick Quote GBT - Free Report incurred a loss of 121 per share in first-quarter 2021 wider than the Zacks Consensus Estimate of a. Global Blood which belongs to the Zacks Medical - Biomedical and Genetics industry posted revenues of 3904 million for the quarter ended March 2021 missing the Zacks.

Wall Street brokerages expect Global Blood Therapeutics Inc. The lowest sales estimate is. Global Blood which belongs to the Zacks Medical - Biomedical and Genetics industry posted revenues of 3904 million for the quarter ended March 2021 missing the Zacks.

You are now leaving the Global Blood Therapeutics website You are currently leaving our site. Global Blood Therapeutics Inc. The firm presently has a 4500 price objective on the stock.

Eleven analysts have made estimates for Global Blood Therapeutics earnings. Get the latest broker recommendations from Zacks Investment Research. Global Blood Therapeutics Inc.

Equities analysts predict that Global Blood Therapeutics Inc. Global Blood Therapeutics has a beta of 139 meaning that. Global Blood Therapeutics reported sales of 1412 million in the same quarter last.

The market expects Global Blood Therapeutics. Global Blood Therapeutics Inc. Global Bloodcurrently carries a Zacks Rank 5 Strong Sell.

Global Blood Therapeutics GBT came out with a quarterly loss of 121 per share versus the Zacks Consensus Estimate of a loss of 102. NASDAQGBT to post sales of 4451 million for the current fiscal quarter Zacks reports. G lobal Blood Therapeutics GBT came out with a quarterly loss of 097 per share versus the Zacks Consensus Estimate of a loss of 072.

GBT incurred a loss of 97 cents per share in third-quarter 2020 which was narrower than a. Global Blood which belongs to the Zacks Medical - Biomedical and Genetics industry posted revenues of 3689 million for the quarter ended September 2020 missing the Zacks. They do not constitute an endorsement or an approval by Global Blood Therapeutics.

The lowest sales estimate is 4000 million and the highest is 4744 million. Get the latest Global Blood Therapeutics Inc. According to Zacks analysts expect that Global Blood Therapeutics will report full year sales of 20602 million for the current financial year with estimates ranging from 16830 million to.

Zacks Investment Research s price target would indicate a potential upside of 453 from the stocks previous close. Ten analysts have made estimates for Global Blood Therapeutics earnings. This compares to loss of 120 per share a year ago.

Zacks proprietary data indicates that Global Blood Therapeutics Inc. Get the latest Detailed Estimate from Zacks Investment Research. Is currently rated as a Zacks Rank 4 and we are looking for a below average return from the GBT shares relative to.

Given Global Blood Therapeutics higher probable upside equities research analysts clearly believe Global Blood Therapeutics is more favorable than Xenetic Biosciences.

Global Blood Therapeutics Gbt Reports Q4 Loss Tops Revenue Estimates Nasdaq